Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.
Frequently asked questions
What sector does BioMark Diagnostics Inc (BMKDF) operate in?
BioMark Diagnostics Inc belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is BioMark Diagnostics Inc (BMKDF) current stock price?
As of the latest data, BioMark Diagnostics Inc stock price is $0.33, with a previous close of $0.33.
What is BioMark Diagnostics Inc (BMKDF) current market capitalization?
BioMark Diagnostics Inc market cap is approximately 35.03 million.
What is BioMark Diagnostics Inc (BMKDF) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
What is BioMark Diagnostics Inc (BMKDF) EBITDA?
BioMark Diagnostics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -169.70 thousand.
Does BioMark Diagnostics Inc (BMKDF) pay dividends?
No. BioMark Diagnostics Inc does not pay a dividend.
What is BioMark Diagnostics Inc (BMKDF) beta (volatility) score?
BioMark Diagnostics Inc has a beta of -0.375, indicating lower volatility than the overall market.